Answers are grounded in this paper and cite their sources.
The combination of two noncompeting human mAbs CR3014 and CR3022 potentially controls immune escape and extends the breadth of protection. At the same time, synergy between CR3014 and CR3022 may allow for a lower total antibody dose to be administered for passive immune prophylaxis of SARS-CoV infection.
No takes yet. Share an insight, caveat, or question.
Meulen et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: